Lyase Variant ApPDC-E469G for High ee (S)-Phenylacetylcarbinol Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for the asymmetric synthesis of (S)-Phenylacetylcarbinol (S)-PAC lack high optical purities and are inefficient, with existing chemical and enzymatic processes producing low enantiomeric excesses and generating by-products or requiring costly separation steps.
Innovation Solution
A variant of the lyase ApPDC-E469G is developed, where isoleucine at position 468 is replaced by a smaller amino acid, and tryptophan at position 543 is also replaced, enhancing stereoselectivity, allowing for the production of (S)-Phenylacetylcarbinol with high enantiomeric excess using benzaldehyde and pyruvate or acetaldehyde without forming by-products or regioisomers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical asymmetric synthesis methods are used to produce (S)-PAC, then the production process is established, but the enantiomeric excess is limited to 68-86% and additional separation steps are required
Solution Approach 1:
The patent replaces chemical catalysis with a biological enzyme system (pyruvate decarboxylase variant) to achieve asymmetric synthesis. The enzyme naturally provides high stereoselectivity without requiring mechanical separation equipment, substituting a biochemical mechanism for chemical-catalytic-and-separation processes
Solution Approach 2:
The patent modifies the enzyme's amino acid sequence (specifically position 469 and surrounding residues) to optimize its catalytic properties. This parameter change in the biological catalyst achieves >90% ee, fundamentally improving the manufacturing precision compared to chemical methods
2Manufacturing precision
If enzymatic asymmetric synthesis using pyruvate decarboxylase is used, then high enantiomeric excess of 89% is achieved, but the yield is very low at 2%
Solution Approach 1:
The patent performs multiple parameter optimizations on the pyruvate decarboxylase enzyme: amino acid substitution at position 469 (e.g., E469G), modification of residues at positions 468, 543, and 546, and optimization of reaction conditions (pH 6.5-7.5, temperature 20-30°C, substrate concentrations). These cumulative parameter changes achieve both high ee (>90%) and high yield (>80%), resolving the contradiction between precision and productivity
Solution Approach 2:
The patent creates a dynamic optimization process where enzyme variants are systematically screened and reaction conditions are adjusted based on performance feedback. This dynamic approach allows simultaneous improvement of both stereoselectivity and conversion efficiency
3Manufacturing precision
If oxidation of 1-phenylpropane-1,2-diol is used to produce (S)-PAC, then enantiomeric excess of 69-91% is achieved, but regioisomers are formed requiring complex separation
Solution Approach 1:
The patent replaces oxidation chemistry with enzymatic carboligation catalyzed by modified pyruvate decarboxylase. This biochemical substitution eliminates the formation of regioisomers that plague oxidation methods, as the enzyme's active site geometry ensures exclusive formation of the desired (S)-PAC product
Solution Approach 2:
The patent converts the enzyme's natural decarboxylation activity, which could lead to byproduct formation, into a beneficial carboligation reaction that produces only the desired chiral product. The enzyme's mechanism is harnessed to prevent rather than create harmful byproducts
4Ease of manufacture
If heterologous expression of pyruvate decarboxylase in Escherichia coli is used, then production in whole cells is achieved, but the optical purity is only 43% ee
Solution Approach 1:
The patent applies amino acid substitutions to the pyruvate decarboxylase gene before heterologous expression, specifically modifying residues at positions 469 (e.g., E to G), 468, 543, and 546. These parameter changes in the genetic sequence directly translate to improved stereoselectivity in whole-cell production, achieving >90% ee while maintaining the ease of whole-cell manufacturing
Solution Approach 2:
The patent performs preliminary enzyme engineering and optimization before the heterologous expression step. By pre-modifying the enzyme's amino acid sequence to enhance stereoselectivity, the patent ensures that whole-cell production immediately yields high optical purity products without requiring post-expression optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves enantiomeric excesses of up to 98% using whole cells or crude cell extracts, eliminating the need for costly separation and using inexpensive unchiral starting materials, thereby overcoming the limitations of previous methods.
Implementation Method 1
a variant of the enzyme pyruvate decarboxylase. Acetobacter pasteurianus the Ap PDC-E469G, catalyzed
Implementation Method 2
enzymatic asymmetric synthesis is known, which is described in the 2013 dissertation by Älvaro Gómez Baraibar entitled 'Development of a biocatalytic production process for (S)-alpha-hydroxy ketones'
Data Source
Figure 1
AI summary
The invention relates to a lyase and to a method for asymmetric synthesis of (S)-phenylacetylcarbinol. According to the invention, a lysase is provided in which the isoleucine is substituted at position no. 468 in the protein ApPDC-E469G, which is modified in comparison to the wild type protein from Aceobacter pasteurianus, with an amino acid that occupies less space than isoleucine. In an advantageous embodiment, the amino acid tryptophan in position no. 543 of the enzyme according to the invention is replaced by a different amino acid that occupies less space than tryptophan. The enzymes according to the invention can be used for asymmetric synthesis of (S)-phenylacetylcarbinol. Enantiomeric excesses of up to 98 % ee can thereby be achieved.